Loading...
•
Sep 30, 2023
Viking Therapeutics Q3 2023 Earnings Report
Viking Therapeutics reported financial results for Q3 2023 and provided a corporate update.
Key Takeaways
Viking Therapeutics reported a net loss of $22.5 million, or $0.23 per share, for the third quarter ended September 30, 2023. The company's cash position remained strong at $376 million. Clinical trials for VK2735 and VK2809 are progressing, with results expected in 1H24.
Phase 2 VENTURE Trial of GLP-1/GIP Agonist VK2735 in Obesity Fully Enrolled; Results Expected 1H24
Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH and Fibrosis Ongoing; Histology Results Expected 1H24
Phase 1 Trial of Oral VK2735 Continues to Enroll; Results Expected 1Q24
Strong Quarter-End Cash Position of $376M
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...